Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

882
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
882

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

JCO precision oncology·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Enhancing Catheter-Assisted C-Arm CT-Guided Ablation with PET/CT Fusion: A Pictorial Overview of Multimodal Synergy for Improving Local Tumor Control in Liver Metastasis.

Cancers·2026
Same author

Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy.

Nature communications·2026
Same author

Discovery of MK-1088 as a Potent A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy.

Journal of medicinal chemistry·2026
Same author

Integration of palliative care into phase I oncology trials: A qualitative interview study with patients, informal caregivers, and healthcare providers.

PloS one·2026

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.6K

Immune Checkpoint-Induced Colitis: A Single-Center Retrospective Cohort Study.

Bengt Van Holder1,2, Julie Vereecke2,3, Nathan Ureel2

  • 1Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.

Journal of Clinical Medicine
|October 29, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitor (ICI) colitis is often microscopic, even with normal endoscopies. Combination ICI therapy predicts steroid resistance, suggesting early biological treatment is needed for effective management of ICI-induced colitis.

Keywords:
colitisimmune-related adverse eventsimmunotherapyinfliximabvedolizumab

More Related Videos

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.1K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.4K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.6K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.1K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.4K

Area of Science:

  • Oncology
  • Gastroenterology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment but can cause immune-related adverse events, notably colitis.
  • Understanding and managing ICI-induced colitis is crucial due to the increasing use of these therapies.

Purpose of the Study:

  • To detail the clinical, endoscopic, and histological characteristics of ICI-induced colitis.
  • To assess treatment outcomes for ICI-induced colitis using corticosteroids and biologicals in a real-world setting.

Main Methods:

  • A retrospective cohort study of 77 adult patients with ICI-induced colitis (2012-2023).
  • Analysis of clinical, biochemical, endoscopic, histological data, and treatment response/safety outcomes.

Main Results:

  • Microscopic colitis was found in 88% of patients with normal endoscopic findings.
  • Combination ICI therapy correlated with higher Mayo scores and greater need for biologicals (p=0.011).
  • Clinical response rates were 79.6% for corticosteroids and 100% for biologicals; ICI rechallenge had a 17.4% relapse rate.

Conclusions:

  • Microscopic findings on random biopsies are common in ICI-induced colitis, even without endoscopic signs.
  • Combination ICI therapy may indicate a need for early escalation to biologicals due to corticosteroid resistance.
  • ICI rechallenge is feasible with manageable colitis morbidity, though prospective studies are warranted.